KP and other cutaneous reactions caused by RAF inhibitors resemble skin changes included in the clinical spectrum of the so-called RASopahies, rare genetic disorders with activating RAS/MAPK germline mutations, and RAF inhibitors can cause paradoxical RAS activation [43,44]. Here, RAF1 is linked to hereditary disease.